XML 21 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1

Intangible Assets

9 Months Ended

Oct. 31, 2017

Intangible Assets [Abstract]

INTANGIBLE ASSETS

7. INTANGIBLE ASSETS

In May 2017, the Company acquired the rights, title and interest in Transdermal Patch and Formulation. As of October 31, 2017, the Company has not recognized any income or cash flow from the use of the patents. The patents are provisional patents and the Company will have one year from the date of issue to finalize the applications. The Company will continue its plans to utilize the patents. The patents are amortized over its useful life of 10 years.

The components of intangible assets are as follows:

	Patents
	Balance February 1, 2017		$	-
	Acquisition of patents in 2017			2,500,000
	Amortization for the period ended October 31, 2017			(110,445	)
	Balance October 31, 2017		$	2,389,555

X

- References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416

+ Details

Name:	us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration